新冠肺炎疫情期间药物临床试验管理指导原则(试行)

2020-07-14 国家药品监督管理局药品审评中心(CDE) CDE

为规范我国新冠肺炎疫情期间的药物临床试验,提供有效的安全管理措施,在国家药品监督管理局的部署下,药审中心组织制定了《新冠肺炎疫情期间药物临床试验管理指导原则(试行)》(见附件)。根据《国家药监局综合司

中文标题:

新冠肺炎疫情期间药物临床试验管理指导原则(试行)

发布日期:

2020-07-14

简要介绍:

为规范我国新冠肺炎疫情期间的药物临床试验,提供有效的安全管理措施,在国家药品监督管理局的部署下,药审中心组织制定了《新冠肺炎疫情期间药物临床试验管理指导原则(试行)》(见附件)。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》(药监综药管〔2020〕9号)要求,经国家药品监督管理局审核同意,现予发布,自发布之日起施行。
       特此通告。
                                                                                                                           国家药品监督管理局药品审评中心
                                                                                                                                         2020年7月14日

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.docx)] GetToolGuiderByIdResponse(projectId=1, id=4bd201c002116e4e, title=新冠肺炎疫情期间药物临床试验管理指导原则(试行), enTitle=, guiderFrom=CDE, authorId=0, author=, summary=为规范我国新冠肺炎疫情期间的药物临床试验,提供有效的安全管理措施,在国家药品监督管理局的部署下,药审中心组织制定了《新冠肺炎疫情期间药物临床试验管理指导原则(试行)》(见附件)。根据《国家药监局综合司, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心(CDE), associationIntro=国家药品监督管理局药品审评中心(CDE), copyright=0, guiderPublishedTime=Tue Jul 14 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>为规范我国新冠肺炎疫情期间的药物临床试验,提供有效的安全管理措施,在国家药品监督管理局的部署下,药审中心组织制定了《新冠肺炎疫情期间药物临床试验管理指导原则(试行)》(见附件)。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》(药监综药管〔2020〕9号)要求,经国家药品监督管理局审核同意,现予发布,自发布之日起施行。<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 特此通告。<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 国家药品监督管理局药品审评中心<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2020年7月14日</p>, tagList=[TagDto(tagId=99273, tagName=新冠肺炎)], categoryList=[CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2419, appHits=51, showAppHits=0, pcHits=431, showPcHits=2368, likes=1, shares=4, comments=2, approvalStatus=1, publishedTime=Sun Jun 27 10:06:45 CST 2021, publishedTimeString=2020-07-14, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sun Jun 27 10:02:39 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 00:44:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.docx)])
66.docx
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=996709, encodeId=6332996e095a, content=理学主题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Tue Jul 06 09:21:50 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977380, encodeId=bae19e738074, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94185531840, createdName=北山布丁, createdTime=Sun Jun 27 19:15:41 CST 2021, time=2021-06-27, status=1, ipAttribution=)]
    2021-07-06 ms3000001999514966

    理学主题

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=996709, encodeId=6332996e095a, content=理学主题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Tue Jul 06 09:21:50 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977380, encodeId=bae19e738074, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94185531840, createdName=北山布丁, createdTime=Sun Jun 27 19:15:41 CST 2021, time=2021-06-27, status=1, ipAttribution=)]
    2021-06-27 北山布丁

    学习

    0